Conclusion GLP-1based therapies are reshaping how clinicians approach cardiometabolic risk
Current evidence from large-scale clinical trials and regulatory surveillance does not establish a causal link between GLP-1 receptor agonists and increased risk of venous thromboembolism (deep vein thrombosis or pulmonary embolism)
Prediabetes itself can sometimes count as a qualifying comorbidity for this pathway, depending on the insurer
Why Cannabis Use Matters Before Starting the First GLP-1 Dose Cannabis use should be discussed before starting GLP-1 medications because it can affect appetite, nausea, vomiting, hydration, digestion, blood sugar awareness, and how side effects are interpreted
Here is what the research shows for properly stored, sealed vials: Room temperature storage Lyophilized peptides can survive at room temperature for several weeks without significant degradation
These natural peptides run everything from energy production and tissue repair to inflammation control and hormone pulsing